PL3458052T3 - Leczenie skojarzone nowotworu - Google Patents

Leczenie skojarzone nowotworu

Info

Publication number
PL3458052T3
PL3458052T3 PL17726573T PL17726573T PL3458052T3 PL 3458052 T3 PL3458052 T3 PL 3458052T3 PL 17726573 T PL17726573 T PL 17726573T PL 17726573 T PL17726573 T PL 17726573T PL 3458052 T3 PL3458052 T3 PL 3458052T3
Authority
PL
Poland
Prior art keywords
cancer therapy
combined cancer
combined
therapy
cancer
Prior art date
Application number
PL17726573T
Other languages
English (en)
Inventor
Nils Aage Brünner
Palle Christophersen
Jan Stenvang
Jens Lichtenberg
Annemette Thougaard
Original Assignee
Scandion Oncology A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scandion Oncology A/S filed Critical Scandion Oncology A/S
Publication of PL3458052T3 publication Critical patent/PL3458052T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17726573T 2016-05-17 2017-05-17 Leczenie skojarzone nowotworu PL3458052T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670325 2016-05-17
PCT/EP2017/061823 WO2017198700A1 (en) 2016-05-17 2017-05-17 Combination treatment of cancer
EP17726573.3A EP3458052B1 (en) 2016-05-17 2017-05-17 Combination treatment of cancer

Publications (1)

Publication Number Publication Date
PL3458052T3 true PL3458052T3 (pl) 2020-06-29

Family

ID=58800797

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19205104T PL3622953T3 (pl) 2016-05-17 2017-05-17 Leczenie skojarzone nowotworu
PL17726573T PL3458052T3 (pl) 2016-05-17 2017-05-17 Leczenie skojarzone nowotworu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19205104T PL3622953T3 (pl) 2016-05-17 2017-05-17 Leczenie skojarzone nowotworu

Country Status (19)

Country Link
US (2) US11103481B2 (pl)
EP (3) EP3458052B1 (pl)
JP (1) JP7033554B2 (pl)
CN (4) CN109475535A (pl)
AU (1) AU2017266724B2 (pl)
BR (1) BR112018073518A2 (pl)
CA (1) CA3023202A1 (pl)
CY (2) CY1122541T1 (pl)
DK (2) DK3622953T3 (pl)
ES (2) ES2770374T3 (pl)
HR (2) HRP20200076T1 (pl)
HU (2) HUE053744T2 (pl)
LT (2) LT3458052T (pl)
PL (2) PL3622953T3 (pl)
PT (2) PT3622953T (pl)
RS (2) RS59844B1 (pl)
SI (2) SI3622953T1 (pl)
SM (2) SMT202000053T1 (pl)
WO (1) WO2017198700A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053744T2 (hu) * 2016-05-17 2021-07-28 Scandion Oncology As A rák kombinált kezelése
US11530181B2 (en) 2018-02-22 2022-12-20 University Of Florida Research Foundation, Incorporated IL-6 inhibitors and methods of treatment
WO2020049139A1 (en) * 2018-09-06 2020-03-12 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
WO2020079051A1 (en) 2018-10-16 2020-04-23 Scandion Oncology A/S Compounds for treatment of microbial infection
EP4104834A1 (en) 2021-06-14 2022-12-21 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
EP4355323A1 (en) 2021-06-14 2024-04-24 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
US20250262188A1 (en) 2021-06-14 2025-08-21 Scandion Oncology A/S Methods of Increasing the Plasma Drug Exposure of Anticancer Agents
TW202321205A (zh) 2021-07-16 2023-06-01 丹麥商斯坎丁腫瘤公司 Sco-101的熱力穩定形式
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN117229258B (zh) * 2022-06-07 2024-07-19 杭州壹瑞医药科技有限公司 N-四唑基芳基脲类衍生物及其制备方法和应用
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
WO2024013058A1 (en) 2022-07-11 2024-01-18 Scandion Oncology A/S Salts of sco-101 and methods involving salts
WO2025125679A1 (en) 2023-12-15 2025-06-19 Scandion Oncology A/S Improved anti-cancer treatment regimen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
RU2197482C2 (ru) 1997-04-22 2003-01-27 НьюроСёрч А/С Замещенные фенильные производные, способ их получения, содержащая их фармацевтическая композиция и способ лечения (варианты)
EE04849B1 (et) 1998-10-22 2007-06-15 Neurosearch A/S Asendatud fenüülderivaadid, nende valmistamine jakasutamine
CN1671378A (zh) 2002-08-01 2005-09-21 神经研究公司 用于治疗对抗血管生成疗法有应答的疾病的化合物
CA2529806A1 (en) 2003-06-17 2004-12-23 Neurosearch A/S Diphenylurea derivatives and their use as chloride channel blockers
US7674899B2 (en) 2004-02-04 2010-03-09 Neurosearch A/S Dimeric azacyclic compounds and their use
MX2007007029A (es) 2004-12-17 2007-08-08 Neurosearch As Derivados de difenilurea utiles como activadores del canal de potasio.
AU2007224457A1 (en) 2006-03-14 2007-09-20 Neurosearch A/S Diphenylurea derivatives and their use as chloride channel blockers or BKca channel modulators
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
TWI508954B (zh) * 2012-04-27 2015-11-21 Nat Defense Medical Ct 雜環融合蒽醌衍生物、其製備方法與醫藥組合物
EP2919009B1 (en) 2014-03-10 2018-09-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft LRRC8 proteins and protein complexes and methods for identification of channel modulators
EP3064207B1 (en) 2015-03-04 2017-12-20 Scandion Oncology A/S 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments
HUE053744T2 (hu) * 2016-05-17 2021-07-28 Scandion Oncology As A rák kombinált kezelése

Also Published As

Publication number Publication date
CN119564679A (zh) 2025-03-07
JP2019519506A (ja) 2019-07-11
CY1122541T1 (el) 2021-01-27
LT3458052T (lt) 2020-02-10
HUE053744T2 (hu) 2021-07-28
BR112018073518A2 (pt) 2019-03-19
EP3458052A1 (en) 2019-03-27
US11903927B2 (en) 2024-02-20
ES2870805T3 (es) 2021-10-27
CN119548494A (zh) 2025-03-04
AU2017266724B2 (en) 2022-04-14
CN119548493A (zh) 2025-03-04
DK3458052T3 (da) 2020-02-03
CN109475535A (zh) 2019-03-15
WO2017198700A1 (en) 2017-11-23
EP3622953A1 (en) 2020-03-18
EP3458052B1 (en) 2019-11-06
US20210353596A1 (en) 2021-11-18
SMT202100245T1 (it) 2021-05-07
HUE047542T2 (hu) 2020-04-28
PT3622953T (pt) 2021-04-21
JP7033554B2 (ja) 2022-03-10
ES2770374T3 (es) 2020-07-01
DK3622953T3 (da) 2021-04-26
CY1124242T1 (el) 2022-07-22
SI3622953T1 (sl) 2021-05-31
HRP20210572T1 (hr) 2021-05-14
CA3023202A1 (en) 2017-11-23
AU2017266724A1 (en) 2018-12-20
EP3622953B1 (en) 2021-03-17
EP3854393A1 (en) 2021-07-28
RS61786B1 (sr) 2021-06-30
PT3458052T (pt) 2020-02-03
US11103481B2 (en) 2021-08-31
HRP20200076T1 (hr) 2020-04-03
PL3622953T3 (pl) 2021-08-16
LT3622953T (lt) 2021-04-26
SMT202000053T1 (it) 2020-03-13
US20190269654A1 (en) 2019-09-05
RS59844B1 (sr) 2020-02-28
SI3458052T1 (sl) 2020-04-30

Similar Documents

Publication Publication Date Title
EP3463464A4 (en) ASSOCIATION TREATMENT
IL261468A (en) Uterine cancer treatments
IL255261A0 (en) Methods for treating cancer
HUE053903T2 (hu) Kombinációs terápia rák ellen
HUE054012T2 (hu) Kombinációs terápia rák ellen
PL3622953T3 (pl) Leczenie skojarzone nowotworu
DK3423087T3 (da) Kombinationsterapi mod cancer
PL3197456T3 (pl) Leczenie nowotworów
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL265697B1 (en) Treatment of prostate cancer
EP3413927A4 (en) CANCER THERAPY
IL264443A (en) Methods of treating prostate cancer
DK3768830T5 (da) Cancerterapi
DK3576740T3 (da) Cancerbehandling
EP3593139C0 (en) CANCER BIOMARKERS
PL3134119T3 (pl) Leczenie nowotworu
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
DK3408265T3 (da) Terapeutiske forbindelser
IL262851A (en) Combination prime: boost therapy
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
IL264277A (en) Crebbp related cancer therapy
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3407909T3 (da) Cancerbehandling
DK3277325T3 (da) Kombinationsimmunterapi for cancer